Cambridge, UK, May 2021: o2h Ventures are excited to announce that In4Derm, backed by the fund managers “o2h human health EIS fund” has signed an Option and Licensing Agreement based around its pipeline of first-in-class, selective BET inhibitors.
The strategic partnership brings further financial and development support to In4Derm in addition to a novel pipeline for the partner.
Sunil Shah, CEO at o2h Ventures said: “This early discovery stage collaboration will both provide the resources and speed up the time to provide novel drug therapeutics to patients. The first commercial deal for the company is a great platform for the team at In4Derm to develop novel therapeutic programmes”.
Andrew Woodland CSO at In4Derm said: “We are delighted by the progress we are making further to the investment made by o2h Ventures. They have been a highly supportive and value adding strategic investor and contributed to the rapid progress that the company has made.”
In4Derm is a biotech that develops new small molecule drugs for anti-inflammatory and orphan indications. In4Derm is a spin out from the world leading University of Dundee’s School of Life Sciences and has laboratory facilities in Dundee, Scotland.
The partnership will work on the development of In4Derm’s pipeline assets and if successful will lead to circa >$200m in milestone and royalties.
About o2h ventures
The o2h human health Fund was the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information about o2h Ventures Funds, please visit www.o2hventures.com
Media Contact:
Ajit Singh, Marketing Manager, ajit@o2h.com
About In4Derm
In4Derm is a biotech that develops new small molecule drugs for anti-inflammatory and orphan indications. In4Derm is a spin out from the world leading University of Dundee’s School of Life Sciences and has laboratory facilities in Dundee, Scotland.
In4Derm is seeking to discover first in class medicines that provide meaningful benefits for patients. In4Derm is supported by o2h Ventures, Meltwind, Wren Capital, Scottish Enterprise and the University of Dundee.
For more information please visit www.In4Derm.com
Contact:
Tim Sparey Ph.D (CEO) tim@in4derm.com
(+44 (0) 7718864561)
